Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786239 · ClinicalTrials.gov registry record · NA
Omega-3 Dietary Supplements in Schizophrenia
A NA study of Schizophrenia and Bipolar Disorder, sponsored by Delbert Robinson.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01786239: Completed NA study of Schizophrenia and Bipolar Disorder, sponsored by Delbert Robinson.
NCT01786239 is a NA study of Schizophrenia and Bipolar Disorder that has completed, run by Delbert Robinson. The registered enrollment target is 50 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786239, a NA study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Delbert Robinson.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
Primary Outcome
The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Omega-3 capsules
Study Locations (1)
New York
- The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT01786239 record still lists
NCT01786239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower).
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01786239 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01786239 about?
NCT01786239 is a clinical study titled "Omega-3 Dietary Supplements in Schizophrenia". This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
What is the current status of trial NCT01786239?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2015-09.
What conditions does trial NCT01786239 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS.
What interventions are being tested in trial NCT01786239?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Omega-3 capsules (DRUG).
Who is sponsoring clinical trial NCT01786239?
This trial is sponsored by Delbert Robinson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01786239 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01786239's enrollment target sits among peer trials
50 208th of 315 higher than 101 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia